ACR Appropriateness Criteria ® Sinonasal Disease
Claudia Kirsch(The Ohio State University Wexner Medical Center), Rebecca S. Cornelius(University of Cincinnati), Vilaas Shetty(Saint Louis University Hospital), Michael D. Luttrull(The Ohio State University Wexner Medical Center), Asim F. Choudhri(Le Bonheur Children's Hospital), Julie Bykowski(University of California San Diego), Lubdha M. Shah(University of Utah), Rathan M. Subramaniam(American College), David B. Conley(American Academy of Otolaryngology — Head and Neck Surgery), Aseem Sharma(Mallinckrodt (United States)), Sophia C. Symko(Colorado Permanente Medical Group), Diego Nuñez(Harvard University), Kevin L. Berger, Joseph M. Aulino(Vanderbilt University)
Cited by 95
Related Papers
Clinical Practice Guideline: Ménière’s Disease
|Otolaryngology|2020|301
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
|The Lancet Oncology|2021|257
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study
|Journal of Clinical Oncology|2020|119
ACR Appropriateness Criteria Head Trauma
|Journal of the American College of Radiology|2016|117
Appropriate Use Criteria for <sup>18</sup>F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease
|Journal of Nuclear Medicine|2017|99